SecBot SecBot

BIVI

BIOVIE INC.
Nasdaq· Pharmaceutical Preparations· Inc. NV· CIK 0001580149 Biotech & Drug Discovery
$1.24 −0.04 (−3.12%)
Oct 23 4:00 PM ET · prev $1.28
Market cap
$11.1M
Nano cap
Median target
$5.26
+324% · range $5.00–5.51
Next earnings
Nov 9
in 14 days
1 year
−34.4%
from $1.89 · Oct 27
30 days
−19.5%
from $1.54
52-week range
$0.9640–2.28
−46% from high · low Aug 18
Avg volume 20D
193.9K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$49.1K
4 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read BEARISH 6 reports · 90 days
Balance 3 bearish · 1 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 4/6 ·Next Earnings date, Nov 9, 2026
Strongest NEUTRAL BioVie presented Phase 2 ADDRESS-LC data for bezisterim in Long COVID at ANA 2026. The trial did not achieve…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    4 insiders bought $49.1K at an average $2.11. No open-market sales. Price is 41% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 6 added (0 new), 3 trimmed or exited.

  • TrendDOWNTREND

    24% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYDOUBLED605,471$1.2M
RENAISSANCE TECHNOLOGIES LLCADD127,918$248.2K
CITADEL ADVISORS LLCDOUBLED95,952$186.1K
JANE STREET GROUP, LLCADD35,860$69.6K
NORTHERN TRUST CORPADD21,820$42.3K
UBS Group AGDOUBLED2,175$4.2K
WELLS FARGO & COMPANY/MNTRIM10$19.00
OSAIC HOLDINGS, INC.NEAR_EXIT8$15.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jul 2024
12-month targets · 2 analysts

Price is below the lowest target. Median implies +324%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Jul 1, 2024ThinkEquity
INITIATE
INITIATEBuy
Nov 30, 2023Oppenheimer
MAINTAIN
MAINTAINOutperform
Aug 22, 2023Cantor Fitzgerald
REITERATE
REITERATEOverweight
Jul 18, 2023Cantor Fitzgerald
REITERATE
REITERATEOverweight
May 17, 2023Cantor Fitzgerald
REITERATE
REITERATEOverweight
May 17, 2023Oppenheimer
REITERATE
REITERATEOutperform

Insider ledger

Form 4
$49.1K
bought · 4 insiders
$0
sold · 0 insiders
−41.2%
vs their $2.11 cost
DateInsiderTypeValue
Aug 28, 2026
Chappell Amy Suzon
Director
BUY$1.6K
Aug 28, 2026
KIM JOANNE WENDY
Chief Financial Officer
BUY$5.5K
Aug 28, 2026
Palumbo Joseph M
Chief Medical Officer
BUY$10.5K
Aug 27, 2026
DO CUONG V
President & CEO
BUY$31.6K

Earnings setup

Estimates
Nov 9
reports in 14 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY-$0.63-$0.63–-$0.63—$0.00
Next FY-$0.57-$0.57–-$0.57—$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
BIVI Q1 2027 Earnings Scheduled — 2026-11-09
Recent
Oct 19, 2026
FDA
BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting
Phase 2 data from the ADDRESS-LC trial of Bezisterim demonstrated statistically significant improvements versus placebo across fatigue…
Sep 22, 2026
Trial readout
Results Pending: NE3107 (Phase 2) — Completed 47d ago
Trial: NE3107 in Adults With Neurological Symptoms of Long COVID Sponsor: BioVie Inc. Phase: Phase 2 | Completed: 2026-08-06 Conditions: Long COVID…
Sep 15, 2026
Trading halt
Halt Resumed: BIVI — trading resumed after T3 (News and Resumption Times)
Halted 2026-09-15T11:25:00.000Z | Resumed 2026-09-15T12:00:00.000Z
Sep 15, 2026
FDA
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue…
Sep 15, 2026
Trading halt
Trading Halt: BIVI — T1 (News Pending)
BioVie Inc Class A Common Stk | Market: NASDAQ | Code: T1 — News Pending

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Sep 15, 2026Resumption ScheduledResumed
Aug 12, 2026Volatility PauseResumed
Aug 12, 2026Volatility PauseResumed
Aug 12, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 Press
BioVie presented Phase 2 ADDRESS-LC data for bezisterim in Long COVID at ANA 2026. The trial did not achieve…
Impact 5/10
Oct 19, 2026 FDA
BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting
Phase 2 data from the ADDRESS-LC trial of Bezisterim demonstrated statistically significant improvem
Sep 15, 2026 Press
BioVie announced topline Phase 2 ADDRESS-LC trial results for bezisterim in Long COVID. The study failed to achieve…
Impact 6/10
Aug 28, 2026 Insider
Chappell Amy Suzon bought 727 shares
Director @ $2.16 ($1.6K)
Aug 28, 2026 Insider
KIM JOANNE WENDY bought 2,500 shares
Chief Financial Officer @ $2.18 ($5.5K)
Aug 28, 2026 Insider
Palumbo Joseph M bought 4,843 shares
Chief Medical Officer @ $2.16 ($10.5K)
Aug 14, 2026 SEC
BioVie Inc. filed Amendment No. 3 to its S-1 registration statement for a best-efforts offering of up to 16,025,641…
S-1/A — Impact 7/10
Aug 6, 2026 SEC
BioVie filed Amendment No. 2 to its S-1 registration statement for a best-efforts offering of up to 56.4 million…
S-1/A — Impact 7/10

SecBot reports

5 filings · 4 press releases · 1 bullish · 4 bearish
All BIVI filing & press-release reports (9)